Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma.
Kim ES, Serur A, Huang J, Manley CA, McCrudden KW, Frischer JS, Soffer SZ, Ring L, New T, Zabski S, Rudge JS, Holash J, Yancopoulos GD, Kandel JJ, Yamashiro DJ. Kim ES, et al. Among authors: new t. Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11399-404. doi: 10.1073/pnas.172398399. Epub 2002 Aug 12. Proc Natl Acad Sci U S A. 2002. PMID: 12177446 Free PMC article.
Regression of established tumors and metastases by potent vascular endothelial growth factor blockade.
Huang J, Frischer JS, Serur A, Kadenhe A, Yokoi A, McCrudden KW, New T, O'Toole K, Zabski S, Rudge JS, Holash J, Yancopoulos GD, Yamashiro DJ, Kandel JJ. Huang J, et al. Among authors: new t. Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7785-90. doi: 10.1073/pnas.1432908100. Epub 2003 Jun 12. Proc Natl Acad Sci U S A. 2003. PMID: 12805568 Free PMC article.
TNP-470 promotes initial vascular sprouting in xenograft tumors.
Huang J, Frischer JS, New T, Kim ES, Serur A, Lee A, Kadenhe-Chiwishe A, Pollyea DA, Yokoi A, Holash J, Yancopoulos GD, Kandel JJ, Yamashiro DJ. Huang J, et al. Among authors: new t. Mol Cancer Ther. 2004 Mar;3(3):335-43. Mol Cancer Ther. 2004. PMID: 15026554
A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP; Investigators of the Phase 3 Trial of l-Glutamine in Sickle Cell Disease. Niihara Y, et al. Among authors: new tn. N Engl J Med. 2018 Jul 19;379(3):226-235. doi: 10.1056/NEJMoa1715971. N Engl J Med. 2018. PMID: 30021096 Free article. Clinical Trial.
39 results